POZN news.
A little bit higher priced play than we normally discuss ($7.10), but their news about 5 minutes ago securing the European patent for treating migranes might make this a 10-20% runner this afternoon. It's getting nice volume since the news.
Bo
_________________________________________________________________
European Patent Issued to POZEN for Treatment of Migraine
Tuesday January 25, 12:07 pm ET
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jan. 25, 2005--POZEN Inc. (NASDAQ: POZN - News) announced today the issuance of European Patent No. 0957914 (Formulation of 5-HT Agonists) covering its MT 400(TM) technology. MT 400 technology refers to POZEN's proprietary combinations of a triptan (5-HT agonists) and a non-steroidal anti-inflammatory drug (NSAID) for use in the acute treatment of migraine. The European patent designates 18 countries in Europe and is in addition to similar patents issued to POZEN in the United States and Australia. Equivalent patent applications are pending in Canada and Japan.
POZEN is collaborating with GlaxoSmithKline (GSK) in the development of Trexima(TM) for the U.S. market. Trexima is the proposed brand name for a single tablet containing sumatriptan succinate, a 5-HT 1B/1D agonist, and naproxen sodium, an NSAID.
POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.
